AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12848587 — intervention group
Group type: EXPERIMENTAL
Intervention: ALX 111 (parathyroid hormone (1-84), rhPTH (1-84))
Number of subjects: 2600
Study 11045408 — intervention group
Group type: EXPERIMENTAL
Intervention: 200-J monophasic shock
Number of subjects: 154
Study 11045408 — intervention group
Group type: EXPERIMENTAL
Intervention: 200-J biphasic shock
Number of subjects: 154
Study 11045408 — intervention group
Group type: EXPERIMENTAL
Intervention: 130-J biphasic shock
Number of subjects: 154
Study 9483953 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation combined with inspiratory muscle training (IMT), n = 7
Number of subjects: 13
Study 9483953 — intervention group
Group type: COMPARATOR
Intervention: Conventional pulmonary rehabilitation only, n = 6
Number of subjects: 13
Study 8508724 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment
Number of subjects: 59
Study 8508724 — intervention group
Group type: COMPARATOR
Intervention: Standard drug counselling
Number of subjects: 59
Study 3518966 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin (NOR) 400 mg bid for 7 days
Number of subjects: 65
Study 3518966 — intervention group
Group type: COMPARATOR
Intervention: Pipemidic acid (PA) 400 mg bid for 7 days
Number of subjects: 65
Study 29939900 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT (10 × 60 seconds at 90% peak oxygen uptake [V̇o2peak], 1: 1 work to recovery at 50 W)
Number of subjects: 32
Study 29939900 — intervention group
Group type: EXPERIMENTAL
Intervention: CETFAT (continuous endurance training at an intensity equivalent to maximal fat oxidation)
Number of subjects: 32
Study 29939900 — intervention group
Group type: EXPERIMENTAL
Intervention: CETAT (continuous endurance training at an intensity equivalent to anaerobic threshold)
Number of subjects: 32
Study 29939900 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT
Number of subjects: 32
Study 29939900 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT and CETAT
Number of subjects: 32
Study 29939900 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT and CETFAT
Number of subjects: 32
Study 29939900 — intervention group
Group type: COMPARATOR
Intervention: CETAT
Number of subjects: 32
Study 29939900 — intervention group
Group type: COMPARATOR
Intervention: CETFAT
Number of subjects: 32
Study 31313142 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharyngeal Electric Stimulation (PES)
Number of subjects: 15
Study 31221870 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging support (4 messages per week for 6 months)
Number of subjects: 1000
Study 28625650 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1
Number of subjects: 78
Study 28625650 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 + Bevacizumab (Bev)
Number of subjects: 78
Study 26130070 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (5 mg, single intravenous infusion)
Number of subjects: 100
Study 23937063 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive online curriculum
Number of subjects: 121
Study 23937063 — intervention group
Group type: COMPARATOR
Intervention: Written curriculum
Number of subjects: 121
Study 21675445 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver sulfadiazine
Number of subjects: 30
Study 21675445 — intervention group
Group type: COMPARATOR
Intervention: Dry dressing
Number of subjects: 30
Study 19324979 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise interventions
Number of subjects: 11
Study 16893458 — intervention group
Group type: EXPERIMENTAL
Intervention: Email over 10 weeks
Number of subjects: 780
Study 16893458 — intervention group
Group type: EXPERIMENTAL
Intervention: Email within one week
Number of subjects: 780
Study 16893458 — intervention group
Group type: EXPERIMENTAL
Intervention: Website over 10 weeks
Number of subjects: 780
Study 16893458 — intervention group
Group type: EXPERIMENTAL
Intervention: Website within one week
Number of subjects: 780
Study 15264777 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxiplex/SP Gel (1-3 ml) applied at the conclusion of surgery
Number of subjects: 18
Study 15264777 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (control group)
Number of subjects: 18
Study 11424467 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane/epidural anesthesia at 2.0 MAC
Number of subjects: 17
Study 11424467 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane/epidural anesthesia at 1.2 MAC
Number of subjects: 17
Study 11424467 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane/epidural anesthesia at 2.0 MAC
Number of subjects: 17
Study 11424467 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane/epidural anesthesia at 1.2 MAC
Number of subjects: 17
Study 11424467 — intervention group
Group type: COMPARATOR
Intervention: Comparison of BIS at 2.0 MAC between isoflurane and sevoflurane
Number of subjects: 17
Study 11424467 — intervention group
Group type: COMPARATOR
Intervention: Comparison of BIS at 1.2 MAC between isoflurane and sevoflurane
Number of subjects: 17
Study 11424467 — intervention group
Group type: COMPARATOR
Intervention: Comparison of SEF 95 at 2.0 MAC between isoflurane and sevoflurane
Number of subjects: 17
Study 11424467 — intervention group
Group type: COMPARATOR
Intervention: Comparison of SEF 95 at 1.2 MAC between isoflurane and sevoflurane
Number of subjects: 17
Study 9694026 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (1 mg i.v.)
Number of subjects: 34
Study 9694026 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 34
Study 7944469 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal treatment with MMC‐CH
Number of subjects: 113
Study 7944469 — intervention group
Group type: COMPARATOR
Intervention: No anti‐cancer drugs (Control)
Number of subjects: 113
Study 3364181 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic anticoagulation starting 4 days before the operation
Number of subjects: 101
Study 3364181 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic anticoagulation starting on the eve of the operation
Number of subjects: 101
Study 3364181 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative anticoagulation set at an INR of 2.1
Number of subjects: 101
Study 3364181 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative anticoagulation
Number of subjects: 101
Study 31665279 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum‐formed Essix C‐retainers (VFR)
Number of subjects: 104
Study 31665279 — intervention group
Group type: COMPARATOR
Intervention: Bonded cuspid‐to‐cuspid retainers (CTC)
Number of subjects: 104
Study 29135036 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual wavelength picosecond Nd:YAG laser (532 nm and 1,064 nm)
Number of subjects: 29
Study 29135036 — intervention group
Group type: EXPERIMENTAL
Intervention: Picosecond 755 nm alexandrite laser
Number of subjects: 29
Study 28629489 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating less during late pregnancy
Number of subjects: 4011
Study 24720375 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascularized interpositional periosteal‐connective tissue graft (test)
Number of subjects: 20
Study 24720375 — intervention group
Group type: COMPARATOR
Intervention: Free subepithelial connective tissue graft (control)
Number of subjects: 20
Study 23792412 — intervention group
Group type: EXPERIMENTAL
Intervention: MTO intervention
Number of subjects: 2829
Study 23792412 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-move services
Number of subjects: 2829
Study 21398619 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumpectomy followed by radiotherapy (LRT)
Number of subjects: 2612
Study 21398619 — intervention group
Group type: EXPERIMENTAL
Intervention: LRT + Tamoxifen (LRT + TAM)
Number of subjects: 2612
Study 21398619 — intervention group
Group type: COMPARATOR
Intervention: Lumpectomy only (LO)
Number of subjects: 2612
Study 21398619 — intervention group
Group type: COMPARATOR
Intervention: LRT
Number of subjects: 2612
Study 21398619 — intervention group
Group type: COMPARATOR
Intervention: LRT + placebo
Number of subjects: 2612
Study 21398619 — intervention group
Group type: EXPERIMENTAL
Intervention: I‐IBTR
Number of subjects: 2612
Study 21398619 — intervention group
Group type: COMPARATOR
Intervention: All patients (with or without I‐IBTR)
Number of subjects: 2612
Study 19905912 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg + Loratadine 10 mg
Number of subjects: 0
Study 19905912 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone 200 mu g/twice daily
Number of subjects: 0
Study 19905912 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Number of subjects: 0
Study 19905912 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 0
Study 19905912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19905912 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast + Loratadine
Number of subjects: 0
Study 19905912 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 0
Study 19905912 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 0
Study 17023730 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondhand smoke (SHS) exposure
Number of subjects: 19
Study 17023730 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTM1-null genotype
Number of subjects: 19
Study 17023730 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTP1 Ile105 genotype
Number of subjects: 19
Study 17023730 — intervention group
Group type: EXPERIMENTAL
Intervention: Responses to SHS and DEPs
Number of subjects: 19
Study 17023730 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTM1-null and GSTP1 Ile/Ile genotypes
Number of subjects: 19
Study 17023730 — intervention group
Group type: COMPARATOR
Intervention: Clean air exposure
Number of subjects: 19
Study 15492298 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (32 mg once daily)
Number of subjects: 4576
Study 15492298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4576
Study 11119172 — intervention group
Group type: EXPERIMENTAL
Intervention: Biweekly automated telephone assessments with telephone follow‐up by diabetes nurse educators
Number of subjects: 570
Study 11119172 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 570
Study 11119172 — intervention group
Group type: COMPARATOR
Intervention: County clinic patients
Number of subjects: 570
Study 11119172 — intervention group
Group type: COMPARATOR
Intervention: VA patients
Number of subjects: 570
Study 7636321 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hyperthermia and radiotherapy (30.0 Gy in 2 weeks or 34.5 Gy in 3 weeks with heat treatments)
Number of subjects: 69
Study 7636321 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule A: 30.0 Gy with heat twice weekly (4 treatments)
Number of subjects: 69
Study 7636321 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule B: 34.5 Gy with heat once weekly (3 treatments)
Number of subjects: 69
Study 7636321 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule C: 34.5 Gy with heat twice weekly (6 treatments)
Number of subjects: 69
Study 7636321 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hyperthermia and radiotherapy
Number of subjects: 69
Study 7636321 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hyperthermia and radiotherapy (915 MHz)
Number of subjects: 69
Study 2571627 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 5 mg
Number of subjects: 19
Study 2571627 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 19
Study 68844 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin and radiation
Number of subjects: 136
Study 68844 — intervention group
Group type: COMPARATOR
Intervention: Radiation only (Control)
Number of subjects: 136
Study 30617139 — intervention group
Group type: EXPERIMENTAL
Intervention: ABP 215
Number of subjects: 642
Study 30617139 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 642
Study 28388454 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation-phase cognitive therapy (C‐CT)
Number of subjects: 172
Study 28388454 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 172
Study 25418606 — intervention group
Group type: EXPERIMENTAL
Intervention: Short implants (6 mm)
Number of subjects: 101
Study 25418606 — intervention group
Group type: COMPARATOR
Intervention: Long implants (11-15 mm) with sinus grafting
Number of subjects: 101
Study 25476084 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous tracheostomy tube
Number of subjects: 32
Study 25476084 — intervention group
Group type: COMPARATOR
Intervention: Traditional silica gel tube
Number of subjects: 32
Study 22113345 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 μg aleglitazar
Number of subjects: 0
Study 22113345 — intervention group
Group type: EXPERIMENTAL
Intervention: 3000 μg aleglitazar
Number of subjects: 0
Study 22113345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22113345 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg moxifloxacin
Number of subjects: 0
Study 20645218 — intervention group
Group type: EXPERIMENTAL
Intervention: Helping Alliance Questionnaire-I (HAQ-I)
Number of subjects: 142
Study 17620371 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of imipenem-cilastatin (loading dose of 1 g/1 g, followed by 2 g/2 g per 24 h for 3 days)
Number of subjects: 20
Study 17620371 — intervention group
Group type: COMPARATOR
Intervention: Intermittent short-term infusion of imipenem-cilastatin (1 g/1 g three times per day for 3 days, total daily dose 3 g/3 g)
Number of subjects: 20
Study 17620371 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Continuous and Intermittent infusion)
Number of subjects: 20
Study 17620371 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion
Number of subjects: 20
Study 15896431 — intervention group
Group type: EXPERIMENTAL
Intervention: Total daily energy intake of REE x 1.7
Number of subjects: 0
Study 15896431 — intervention group
Group type: COMPARATOR
Intervention: Total daily energy intake of REE x 1.3
Number of subjects: 0
Study 12410192 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (intravenous), administered daily for 3 consecutive days, repeated at 3-month intervals for one year
Number of subjects: 12
Study 12410192 — intervention group
Group type: COMPARATOR
Intervention: Placebo (plain saline, intravenous), administered daily for 3 consecutive days, repeated at 3-month intervals for one year
Number of subjects: 12
Study 12410192 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (intravenous)
Number of subjects: 12
Study 12410192 — intervention group
Group type: COMPARATOR
Intervention: Placebo (plain saline, intravenous)
Number of subjects: 12
Study 9704328 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional ski video
Number of subjects: 763
Study 8916057 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant target frequency of 0.8 Hz for following square step targets with an eccentricity of +/- 20 degrees.
Number of subjects: 0
Study 8916057 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetition of the manoeuvre using the target frequency of 0.8 Hz.
Number of subjects: 0
Study 1924666 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine hydrochloride at 5 mg, 10 mg, or 20 mg daily for 4 weeks
Number of subjects: 72
Study 1924666 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine hydrochloride
Number of subjects: 72
Study 1924666 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine N‐oxide
Number of subjects: 72
Study 6805618 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound isolator
Number of subjects: 291
Study 6805618 — intervention group
Group type: COMPARATOR
Intervention: Standard gamma‐irradiated adhesive dressing
Number of subjects: 291
Study 30194553 — intervention group
Group type: EXPERIMENTAL
Intervention: ESWT with PBMT
Number of subjects: 120
Study 30194553 — intervention group
Group type: EXPERIMENTAL
Intervention: ESWT (once a week)
Number of subjects: 120
Study 30194553 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMT (three times a week)
Number of subjects: 120
Study 30194553 — intervention group
Group type: COMPARATOR
Intervention: Sham-PBMT (three times a week)
Number of subjects: 120
Study 27810267 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐intensity functional exercise program
Number of subjects: 186
Study 27810267 — intervention group
Group type: COMPARATOR
Intervention: Seated attention control activity
Number of subjects: 186
Study 25754414 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro mix (mix 50 before breakfast and lunch plus mix 25 before dinner)
Number of subjects: 402
Study 25754414 — intervention group
Group type: COMPARATOR
Intervention: Basal-bolus therapy (insulin glargine at bedtime plus prandial insulin lispro thrice-daily)
Number of subjects: 402
Study 25754414 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro mix
Number of subjects: 402
Study 25754414 — intervention group
Group type: COMPARATOR
Intervention: Basal-bolus therapy
Number of subjects: 402
Study 25754414 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 402
Study 23581911 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 1699
Study 22014840 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild ischemic mitral regurgitation (IMR)
Number of subjects: 35
Study 22014840 — intervention group
Group type: COMPARATOR
Intervention: Control (no IMR)
Number of subjects: 35
Study 19888840 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot gymnastics group (FG)
Number of subjects: 56
Study 19888840 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (TG)
Number of subjects: 56
Study 19888840 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 56
Study 16713523 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed Consent Questionnaire (ICQ)
Number of subjects: 1092
Study 16713523 — intervention group
Group type: EXPERIMENTAL
Intervention: ICQ-4 (four-item subscale of the ICQ)
Number of subjects: 1092
Study 14691621 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg tramadol (intraarticular)
Number of subjects: 210
Study 14691621 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg tramadol (intraarticular)
Number of subjects: 210
Study 14691621 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg tramadol (intraarticular)
Number of subjects: 210
Study 14691621 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl (intraarticular)
Number of subjects: 210
Study 14691621 — intervention group
Group type: COMPARATOR
Intervention: 100 mg tramadol (intravenous)
Number of subjects: 210
Study 14691621 — intervention group
Group type: COMPARATOR
Intervention: 50 mg tramadol (intravenous)
Number of subjects: 210
Study 14691621 — intervention group
Group type: COMPARATOR
Intervention: 20 mg tramadol (intravenous)
Number of subjects: 210
Study 11771912 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse home visitation program over 2 years
Number of subjects: 0
Study 11771912 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 0
Study 1308699 — intervention group
Group type: EXPERIMENTAL
Intervention: Rich-monounsaturated fat diet (RMF) with avocado
Number of subjects: 16
Study 1308699 — intervention group
Group type: EXPERIMENTAL
Intervention: Free monounsaturated-enriched diet (FME) with avocado
Number of subjects: 16
Study 1308699 — intervention group
Group type: COMPARATOR
Intervention: Low-saturated fat diet (LSF) without avocado
Number of subjects: 16
Study 6741804 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase (STK)
Number of subjects: 28
Study 6741804 — intervention group
Group type: COMPARATOR
Intervention: Intravenous streptokinase (STK)
Number of subjects: 28
Study 6741804 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful recanalization (either route)
Number of subjects: 28
Study 31780038 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotics (500 mg capsule containing Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum plus inulin)
Number of subjects: 60
Study 31780038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 29493868 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 30
Study 29493868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 27172587 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A - three questions about alcohol consumption
Number of subjects: 3594
Study 27172587 — intervention group
Group type: COMPARATOR
Intervention: Group B - seven questions about alcohol dependence followed by three alcohol consumption questions
Number of subjects: 3594
Study 24854414 — intervention group
Group type: EXPERIMENTAL
Intervention: Scrambled kit lists
Number of subjects: 0
Study 24854414 — intervention group
Group type: COMPARATOR
Intervention: Double randomized kit lists
Number of subjects: 0
Study 24854414 — intervention group
Group type: COMPARATOR
Intervention: Blocked kit lists
Number of subjects: 0
Study 22531205 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate administration (minimum 750 mg/d)
Number of subjects: 42
Study 22531205 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of sodium valproate administration
Number of subjects: 42
Study 19963274 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (average daily dose=232mg)
Number of subjects: 0
Study 19963274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19963274 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 0
Study 18622465 — intervention group
Group type: EXPERIMENTAL
Intervention: Chili group
Number of subjects: 50
Study 18622465 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 50
Study 15569820 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (bicycle ergometer at approximately 60% of maximal oxygen consumption for 30 minutes per day, 5 days per week for 8 weeks)
Number of subjects: 30
Study 15569820 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 30
Study 15569820 — intervention group
Group type: EXPERIMENTAL
Intervention: Deconditioning (after 8 weeks of training)
Number of subjects: 30
Study 15569820 — intervention group
Group type: COMPARATOR
Intervention: Control group (sedentary subjects without training)
Number of subjects: 30